

# Kinetic Parameters of $\alpha_2$ -macroglobulin in Rats Induced Nephropathy by Administration of Gentamicin

Takashi Kuribayashi\*, DVM, PhD

Laboratory of Immunology, School of Life and Environmental Science, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan

Corresponding author: Takashi Kuribayashi, Laboratory of Immunology, School of Life and Environmental Science, Azabu University, 1-17-71 Fuchinobe, Chou-ku, Sagamihara, Kanagawa 252-5201, Japan  
E-mail: kuribaya@azabu-u.ac.jp,  
Phone: +81-42-754-7111 (ex375), Fax: +81-42-754-2461

**KEY WORDS:**  $t_{1/2}$ ,  $\alpha_2$ M, Gentamicin, Nephropathic rat

## ABSTRACT

The elimination phase of  $\alpha_2$ -macroglobulin ( $\alpha_2$ M), a typical acute phase protein, in nephropathic rats was investigated.

## Methods

Renal failure was induced by injection of gentamicin. Acute inflammation was induced by injection of turpentine oil in rats. Serum concentrations of  $\alpha_2$ M were measured by enzyme-linked immunosorbent assay. Half-life was calculated as  $0.693/\text{elimination rate constant (K)}$ . The serum concentrations of  $\alpha_2$ M were significantly higher during renal failure than in the control. Moreover, the maximum concentrations and total area under the blood concentration vs. time curve were significantly elevated during renal failure. However, the rate of elimination in nephropathic rats was equivalent to that in control rats. Therefore, no significant difference in the  $\alpha_2$ M half-life was observed between nephropathic and control rats.

## INTRODUCTION

$\alpha_2$ -macroglobulin ( $\alpha_2$ M) is a typical acute phase protein in rats.<sup>1,2</sup> Serum  $\alpha_2$ M concentrations increased more sensitively than

AAG levels in rats following the induction of acute inflammation.<sup>3</sup> While certain characteristics of  $\alpha_2$ M production in rats have been reported,<sup>3,4</sup> there is a limited amount of information regarding the kinetic of  $\alpha_2$ M in disease models. However, alterations in the serum  $\alpha_2$ M concentrations in rats with hepatic impairment have been reported.<sup>5</sup> Nephropathy is known to be a serious adverse event related to aminoglycoside antibiotics.<sup>6</sup> Thus, we used a high dose of an aminoglycoside antibiotic to induce the impairment of renal function in rats in this study. The aim of this study was to clarify the influence of nephropathy on  $\alpha_2$ M elimination rates in rats.

## MATERIALS AND METHODS

### Animals

Ten Sprague-Dawley rats (body weight; 120g~150g) were purchased from CLEA Japan, Inc. (Tokyo, Japan). Rats were housed individually at a temperature of  $23 \pm 2^\circ\text{C}$ , with a relative humidity of  $55 \pm 10\%$  on a 12/12 dark (20:00-8:00)/light (8:00-20:00) cycle. The air was exchanged 12 or more times per hour. Rats were fed MF diet (Oriental Yeast Co., Ltd., Tokyo, Japan) and allowed free access to water. The present animal experiments were approved by the Institutional Animal Care and Use Commit-

**Table 1** Biochemical parameters and kinetic parameters of  $\alpha_2$ -macroglobulin in rats treated with gentamicin (30mg/kg) once a day for five days

Group	Creatinine (mg/dl)	BUN (mg/dl)	Cmax ( $\pm$ g/ml)	K	AUC (mg $\cdot$ hr/ml)	$t_{1/2}$ (hr)
Nephropathy	30* $\pm$ 7	0.33* $\pm$ 0.05	2418.1* $\pm$ 1051.7	0.0065 $\pm$ 0.0025	216.7* $\pm$ 69.2	121.2 $\pm$ 48.7
Control	20 $\pm$ 3	0.24 $\pm$ 0.04	1351.3 $\pm$ 607.3	0.0065 $\pm$ 0.0010	92.9 $\pm$ 26.4	108.7 $\pm$ 18.3

Each value were represented mean  $\pm$  standard deviation., Cmax: maximum concentrations, K: elimination rate constant, AUC: area under the blood concentration vs. time curve,  $t_{1/2}$ : half-life time, \*: Values differs significantly from control rats ( $p < 0.05$ ).

tee of Azabu University.

### Animal Experiments

Nephropathy was induced by daily intravenous administration of gentamicin sulfate (Schering-Plough Corporation, NJ, USA) at a dose of 30 mg/kg for 5 days. Sterile saline was similarly administered in the control group. Acute inflammation was induced by injection of 3 ml/kg body weight turpentine oil (Wako Pure Chemical Industries, Co., Ltd.). Ventricular blood was collected before turpentine oil administration and at 24, 48, 72, 96, 144, 192, 240, 312, and 384 hours post-administration. Blood was collected under slight anesthesia by intravenous injection of 6 mg/kg pentobarbital (Kyoritsu Seiyaku Corporation, Tokyo, Japan). Serum was stored at  $-80^\circ\text{C}$  until analysis.

### $\alpha_2\text{M}$ , BUN and Cr. Measurement

Serum concentrations of  $\alpha_2\text{M}$  were measured according to the procedure of Honjo et al.<sup>7</sup> Blood urea nitrogen (BUN) was measured using the urease  $\cdot$  GLDH method. Creatinine (Cr.) was measured using an enzymatic method.

### Pharmacokinetic Parameters

Maximum concentrations (Cmax) were determined in individual rats. The area under the blood concentration vs. time curve (AUC) from 0 to 384 hours was calculated using the trapezoidal rule. The linear slope of serum  $\alpha_2\text{M}$  concentration vs. time was then plotted on log-linear regression for individual animals. The elimination rate constant (K) was calculated using a minimum of 3 measured serum concentrations.<sup>8</sup> Half-life ( $t_{1/2}$ ) was calculated from the formula:

$$\text{Slope} = \frac{\log C^A - \log C^B}{\text{Time (A)} - \text{Time (B)}}$$

$$K(h^{-1}) = (-2.303) \times \text{slope}$$

$$t_{1/2} (h) = 0.693 / K$$

where, K is the elimination rate constant, CA is serum concentration at Time(A), CB is serum concentration at Time(B)

### Statistical Analysis

Unpaired Student's t-tests were performed to evaluate differences in AUC, K,  $t_{1/2}$ , BUN and Cr. between the nephropathy and control groups; p values of  $< 0.05$  were considered to be significant.


### RESULTS

Serum levels of BUN and Cr. in control and gentamicin-treated rats are shown in Table 1. Both BUN and Cr. were significantly higher in rats treated with gentamicin than in control rats. Serum concentrations and kinetic parameters of  $\alpha_2\text{M}$  are shown in Table 1 and Figure 1, respectively. Except for pre-turpentine oil treatment levels, serum concentrations of  $\alpha_2\text{M}$  were significantly higher in rats treated with gentamicin than in control rats. Cmax and AUC in rats treated with gentamicin were significantly higher than in control rats. However, no significant differences were observed in both K and  $t_{1/2}$  between gentamicin-treated and control rats.

### DISCUSSION

Renal failure is a well-known, serious adverse event associated with the use of aminoglycoside antibiotics.<sup>6,7</sup> Serum levels of BUN and Cr. in rats treated with gentami-

**Figure 1** Serum concentration of  $\alpha_2$ -macroglobulin ( $\alpha_2M$ ) in nephropathy rats treated with gentamicin (30mg/kg). \*: Values differs significantly from control rats ( $p < 0.05$ ).



cin were significantly higher than in control rats, which is indicative of the induction of nephropathy. Serum concentrations of  $\alpha_2M$  have been shown to increase in humans with renal failure.<sup>9, 10</sup> Serum concentrations of  $\alpha_2M$  in nephropathic rats were significant higher than in control rats. Moreover, Cmax and AUC were significant higher than in control rats. These results are congruent with the elevation of  $\alpha_2M$  observed in nephropathic humans. However, the rate  $\alpha_2M$  elimination in nephropathic rats was not different from control rats, with both K and  $t_{1/2}$  not significantly different between groups. Thus, renal failure resulted in increased  $\alpha_2M$  levels, but did not influence its elimination rate. The mechanism of aminoglycoside-induced renal failure is thought to be due to tubular cell toxicity.<sup>11</sup> Elimination rates are not influenced by impairment of the renal tubule. Alterations in elimination rates associated with renal failure are presumed to result from failure of non-tubule sites in the kidney. Thus, further studies aimed at inves-

tigating glomerular injury are required.

## REFERENCES

1. Jinbo T, Motoki M, Yamamoto S. Variation of serum alpha2-macroglobulin concentration in healthy rats and rats inoculated with Staphylococcus aureus or subjected to surgery. *Comp Med* 2001; 51: 332-335.
2. Jinbo T, Sakamoto T, Yamamoto S. Serum alpha2-macroglobulin and cytokine measurements in acute inflammation model in rats. *Lab Anim* 2002; 36: 153-157.
3. Kuribayashi T, Tomizawa M, Seita T, Tagata K, Yamamoto S. Relationship between production of acute-phase proteins and strength of inflammatory stimulation in rats. *Lab Anim* 2011; 45: 215-218.
4. Kuribayashi T, Seita T, Kawato K, Yamazaki S, Yamamoto S. Comparison of  $\alpha_2$ -macroglobulin synthesis by juvenile vs. mature rats after identical inflammatory stimulation. *Inflammation* 2013; 36: 1448-1452.
5. Kuribayashi T, Seita T, Honjo T, Yamazaki S, Momotani E, Yamamoto S. Impairment of  $\alpha_2$ -macroglobulin synthesis in experimental hepatopathic rats treated with turpentine oil. *Exp Anim* 2012; 61: 125-130.
6. Sieber M, Hoffmann D, Adler M, Vaidya VS, Clement M, Bonventre JV, Zidek N, Rached E, Amberg A, Callanan JJ, Dekant W, Mally A. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat

- model of gentamicin nephrotoxicity. *Toxicol Sci* 2009; 109: 336-349.
7. Honjo T, Kuribayashi T, Seita T, Mokonuma U, Yamaga A, Yamazaki S, et al. 2010. The effects of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 on  $\alpha$ 2-macroglobulin production in rats. *Exp Anim* 2010; 59: 589-594.
  8. Veilleux-Lemieux D, Castel A, Carrier D, Beaudry F, Vachon P. Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats. *J Am Assoc Lab Anim Sci* 2013; 52: 567-570.
  9. Housley J. Alpha2-macroglobulin levels in disease in man. *J Clin Path* 1968; 21: 27-31.
  10. Monique GM, Sain-van DV, Rabelink TJ, Reijngoud DJ, Gadellaa MM, Voorbij HAM, Stellaard F, Kaysen GA. Plasma  $\alpha_2$  macroglobulin is increased in nephrotic patients as a result of increased alone. *Kidney Int* 1998; 54: 530-535.
  11. Dhodi DK, Bhagat SB, Pathak D, Patel SB. 2014. Drug-induced nephrotoxicity. *Int J Basic Clin Pharmacol* 2014; 3 591-597.